$178.00 - $4,651.50

$178.00 - $4.00

Choose an Option...
  • 100 mg - $4,651.50
  • 50 mg - $3,286.00
  • 25 mg - $2,183.00
  • 5 mg - $652.00
  • 1 mg - $178.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left
US Customers - Order by Noon EST on Monday to receive by November 17.
You may also be interested in:

Product Description

The human IgG1 isotype control antibody is purified from human myeloma serum and is of unknown specificity. This antibody is suitable for use as a non-targeting isotype control in various in vitro and in vivo studies. It can also be used as a negative control in various diagnostic applications such as ELISA, Western blot, immunofluorescence, immunohistochemistry, immunoprecipitation, and flow cytometry. For research use only.

Specifications

Isotype Human IgG1
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin ≤1EU/mg (≤0.001EU/μg)
Determined by LAL assay
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from human myeloma serum
Purification Protein A
RRID AB_2687817
Molecular Weight 150 kDa
Human Pathogen Test Results Hepatitis B Surface Antigen: Negative
Human Immunodeficiency Virus 1 antibodies: Negative
Human Immunodeficiency Virus 2 antibodies: Negative
Hepatitis C Virus antibodies: Negative
* These tests cannot guarantee the absence of infective agents
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options

Application References

  • Li, M., et al (2019). "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis" Gut 68(6): 1024-1033.

    OBJECTIVES: Patients with gallbladder carcinoma (GBC) lack effective treatment methods largely due to the inadequacy of both molecular characterisation and potential therapeutic targets. We previously uncovered a spectrum of genomic alterations and identified recurrent mutations in the ErbB pathway in GBC. Here, we aimed to study recurrent mutations of genes and pathways in a larger cohort of patients with GBC and investigate the potential mechanisms and clinical significance of these mutations. DESIGN: We performed whole-exome sequencing (WES) in 157 patients with GBC. Functional experiments were applied in GBC cell lines to explore the oncogenic roles of ERBB2/ERBB3 hotspot mutations, their correlation with PD-L1 expression and the underlying mechanisms. ERBB inhibitors and a PD-L1 blocker were used to evaluate the anticancer activities in co-culture systems in vitro and in vivo. RESULTS: WES identified ERBB2 and ERBB3 mutations at a frequency of 7%-8% in the expanded cohort, and patients with ERBB2/ERBB3 mutations exhibited poorer prognoses. A set of in vitro and in vivo experiments revealed increased proliferation/migration on ERBB2/ERBB3 mutation. Ectopic expression of ERBB2/ERBB3 mutants upregulated PD-L1 expression in GBC cells, effectively suppressed normal T-cell-mediated cytotoxicity in vitro through activation of the PI3K/Akt signalling pathway and contributed to the growth and progression of GBC in vivo. Treatment with an ERBB2/ERBB3 inhibitor or a PD-L1 monoclonal antibody reversed these immunosuppressive effects, and combined therapy revealed promising therapeutic activities. CONCLUSIONS: ERBB2/ERBB3 mutations may serve as useful biomarkers in identifying patients who are sensitive to ERBB2/ERBB3 inhibitors and PD-L1 monoclonal antibody treatment. TRIAL REGISTRATION NUMBER: NCT02442414;Pre-results.

Product Citations

  • Functional O-specific polysaccharide-specific antibody responses in young children following Shigella infection in Bangladesh.

    In Cell Rep Med on 20 October 2026 by Bernshtein, B., Zhiteneva, J. A., et al.

    PubMed

    Shigellosis is the second leading cause of diarrheal death in children under 5 years globally, yet no licensed vaccine exists, partly due to poor understanding of protective immunity in young children, especially in endemic settings. Here, we applied a functional antibody-profiling approach to define Shigella-specific antibody responses in young children versus older individuals with culture-confirmed shigellosis in Bangladesh. We found that higher baseline O-specific polysaccharide (OSP)-specific and protein-specific IgG and FcγR binding levels correlated with less severe disease regardless of age. We also found that over time, individuals under 5 years of age developed a less functional and durable response against OSP than older individuals. We demonstrate that OSP-specific IgG increased uptake of live Shigella by monocytes and macrophages in an Fc-dependent mechanism. Our findings suggest that young children develop limited OSP-specific functional antibody responses that fail to maximally involve innate immune cells. Innate cell clearance may be important in protecting against Shigella.

  • Supermeres Containing the Discoidin Domain Receptor 1 Extracellular Domain Promote Collagen Alignment and Immune Exclusion in Microsatellite-Stable Colorectal Cancer.

    In Cancer Res Commun on 1 September 2026 by Hamilton, M. S., Ellis, S. T., et al.

    PubMed

    Immune checkpoint blockade (ICB) is an effective treatment for microsatellite instability-high (MSI-H) colorectal cancers that are highly infiltrated by CD8+ T cells. Microsatellite-stable (MSS) colorectal cancers are unresponsive to ICB, at least in part, due to the paucity of intratumoral CD8+ T cells. We recently identified discoidin domain receptor 1 (DDR1) as one of four genes associated with CD8+ T-cell exclusion in MSS colorectal cancer. There are conflicting reports about the presence and role of the cleaved ectodomain (cECD) of DDR1 in mouse models of breast and pancreatic cancers. To explore the role of the DDR1 cECD in human colorectal cancer, we developed Collagen Alignment and Spatial Transcriptomics Analysis (CASTA), which revealed that genes involved in fibroblast contractility were associated with both DDR1 tumor expression and collagen alignment as determined by label-free second harmonic generation (2HG) imaging of the tumor collagen. Using 3D collagen cocultures of colorectal cancer spheroids and fibroblasts, we show that DDR1 promotes collagen alignment and CD8+ T-cell exclusion. We found large amounts of DDR1 cECD in MSS colorectal cancer supermeres, 25- to 35-nm secreted amembranous nanoparticles. Supermeres containing DDR1 cECD were sufficient to induce contraction of human colonic fibroblasts. We propose a model in which supermeres containing the DDR1 cECD promote the contraction of stromal fibroblasts in MSS colorectal cancer, leading to collagen alignment and CD8+ T-cell exclusion. These results support DDR1 cECD as an attractive therapeutic target in MSS colorectal cancer.

  • Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance.

    In Cell on 20 August 2026 by Lei, G., Lu, Z., et al.

    PubMed

    Cuproptosis is a recently identified form of copper-dependent cell death that depends on ferredoxin 1 (FDX1)-mediated protein lipoylation. Here, we reveal that CD8+ T cell-mediated antitumor immunity enhances tumor cell susceptibility to cuproptosis, leading to a more potent tumor-suppressive effect of cuproptosis inducers in immunocompetent hosts compared with immunodeficient ones. Mechanistically, cuproptotic tumor cells act as a form of immunogenic cell death, releasing damage-associated molecular patterns that activate dendritic cells and enhance antitumor immunity. Reciprocally, CD8+ T cell-derived interferon (IFN)-γ enhances FDX1 transcription in tumor cells by activating the signal transducer and activator of transcription 1 (STAT1)-IFN regulatory factor-1 (IRF1) signaling axis, resulting in heightened tumor cell sensitivity to cuproptosis. Consequently, combining a cuproptosis inducer with anti-programmed cell death ligand 1 (PD-L1) therapy amplifies tumoral cuproptosis and demonstrates efficacy in overcoming PD-L1 therapy resistance across multiple preclinical models. Our findings unveil a previously unrecognized connection between antitumor immunity and cuproptosis and highlight a potential therapeutic approach to counteract tumor immunotherapy resistance by targeting this unique cell death pathway.

  • Signaling downstream of tumor-stroma interaction regulates mucinous colorectal adenocarcinoma apicobasal polarity.

    In Nat Commun on 4 July 2026 by Pasquier, N., Pelkonen, M., et al.

    PubMed

    Mucinous colorectal carcinoma (MUC CRC) metastasis to multiple organs, and to the peritoneum, is associated with poor prognosis. Disseminating MUC CRCs exhibit either conventional (apical-in) or inverted (apical-out) polarity that influence patient outcomes. Therefore, it is critical to identify how MUC CRC polarity is regulated. Here, we analyze patient-derived MUC CRC xenografts with either apical-in or apical-out polarity. Single-cell analyses reveal α2β1-integrin as a key collagen-binding receptor in these models. Collagen-α2β1-integrin interaction activates Src and upregulates SorLA, an endosomal sorting receptor. SorLA supports apical-in polarity by promoting integrin recycling and HER2/HER3 expression. We observe positive correlation between HER2, HER3 and SorLA in patient samples and higher HER2 expression in apical-in-presenting tissues. Clinically relevant HER2/HER3-targeting antibodies revert tumor sphere polarity, and impede collagen remodeling and adhesion to mouse peritoneum. This SorLA-integrin-HER2/HER3 axis could represent a MUC CRC-patient stratification approach and be relevant for other carcinomas with apical-out phenotypes.

Product FAQs

Related Products

  1. Catalog #CP160
    RecombiMAb mouse IgG2a isotype control, unknown specificity Read more
  2. Catalog #BE0369
    InVivoMAb polyclonal llama IgG Read more
  3. Catalog #BP0290
    InVivoPlus rat IgG1 isotype control, anti-trinitrophenol Read more
  4. Catalog #BP0087
    InVivoPlus polyclonal Syrian hamster IgG Read more
  5. Catalog #BE0087
    InVivoMAb polyclonal Syrian hamster IgG Read more
  6. Catalog #BE0094
    InVivoMAb polyclonal rat IgG Read more
  7. Catalog #BE0095
    InVivoMAb polyclonal rabbit IgG Read more
  8. Catalog #BE0093
    InVivoMAb polyclonal mouse IgG Read more
  9. Catalog #BE0092
    InVivoMAb polyclonal human IgG Read more
  10. Catalog #BE0130
    InVivoMAb polyclonal goat IgG Read more
  11. Catalog #BE0290
    InVivoMAb rat IgG1 Isotype control, anti-trinitrophenol Read more
  12. Catalog #BE0091-FAB
    InVivoMAb hamster IgG f(ab')2 fragments Read more
  13. Catalog #CP130
    RecombiMAb anti-mouse CD71 (TfR1) Read more

Additional Formats